NASDAQ:SYRE

Analysts Viewpoint

0 analysts rank SYRE stock as an Overweight

Daniel Torres

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its ...

News

Insider Selling: Turtle Cameron, Spyre Therapeutics Inc [SYRE] Chief Executive Officer divested 15,000 shares

Jaxson Clark

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its ...

Analysts Viewpoint

Positive sentiment towards SYRE reflected by a fall of -11.2% in short interest

Anna Perez

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Spyre Therapeutics ...

Analysts Viewpoint

Short interest on SYRE sees a significant decrease on 2025-11-28

Jaxson Clark

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its ...

Knox Daily
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.